If you are having trouble viewing this e-mail, click here to view it online.

CURExtra ASCO edition
curextra: calendar, archives, and CURE Magazine



Cancer Treatment Gets Personal

Cancer Treatment Gets Personal


More than 30,000 oncologists, researchers, and industry representatives from around the world gathered in Orlando in late May for the largest oncology meeting of the year. Scientists presented data that will change patient care, as well as updates in treatment, prevention, supportive care, translational medicine, and other cancer-related topics.  [MORE]

Debu Tripathy's Blog

Elizabeth Whittington's Blog

Debu Tripathy, MD

New class of drugs show off at ASCO

What happens when a preliminary study that was not designed for drug approval ends up showing dramatic results?  [MORE]

Elizabeth Whittington

How do we improve clinical trial participation?

Physicians, researchers, and industry officials gathered to discuss the reasons for slow trial accrual and ways to improve it. [MORE]

Susan McClure's Blog

Melissa Weber's Blog

Susan McClure

When cancer breakthroughs hit home

For someone who may have had triple-negative breast cancer, the news on PARP inhibitors was a small personal victory.


Melissa Weber

Study shows how to prevent rash from EGFR Inhibitors

Doctors now know how to prevent the skin rash that develops in up to 90 percent of patients receiving these drugs. [MORE]


story separator

orange arrow

Highlights From the 2009 ASCO Annual Meeting

PARP Inhibitors Successful Against Hard-to-Treat Breast Cancers

A new class of drugs called PARP inhibitors is getting some serious attention after a study in metastatic triple-negative breast cancer patients found that the agent BSI-201 significantly improved survival. [MORE]

Zactima Delays Advanced Lung Cancer Growth

An international phase III trial found the investigational lung cancer drug, Zactima (vandetanib), significantly slowed the time a patient’s advanced lung cancer progressed. [MORE]

Antidepressants Reduce the Effectiveness of Tamoxifen

Taking tamoxifen with certain drugs that treat depression and hot flashes may reduce the cancer drug’s ability to prevent breast cancer recurrence. [MORE]

Herceptin Improves Survival in Gastric Cancer

The breast cancer drug Herceptin (trastuzumab) extends survival in certain gastric cancer patients by almost three months, according to a phase III international study. [MORE]

Therapeutic Vaccine Delays Lymphoma Recurrence

Researchers of a follicular lymphoma trial hope that BiovaxID, a personalized vaccine, could help delay recurrences. [MORE]

CA-125 Monitoring Not Helpful for Ovarian Cancer Survivors

Results from an international study challenge the current practice of screening for ovarian cancer relapse. [MORE]

Trial Confirms Benefit of Targeted Combination in Lung Cancer

A large phase III study, which examined whether the addition of Tarceva (erlotinib) to Avastin (bevacizumab) delayed progression of advanced non-small cell lung cancer, reached its primary goal. [MORE]

Avastin Successful With Various Chemotherapies

in Breast Cancer

Adding Avastin to standard therapy delayed progression of advanced HER2-negative breast cancer in women without prior treatment. [MORE]

New Test Predicts Colon Cancer Recurrence

For the first time, a test can predict which patients with stage 2 colon cancer are more likely to have a recurrence. [MORE]

Avastin Falls Short in Early-Stage Colon Cancer

Adding Avastin (bevacizumab) to standard chemotherapy after surgery failed to extend the time early-stage colon cancer patients were free of recurrence. [MORE]

 story separator

Become a fan of CURE on Facebook

Follow CURE on Twitter

Submit your personal experience essays to editor@curetoday.com

To purchase a back issue, click here.

Sign up for our e-mail newsletters, which you can now personalize by tumor type, survivorship, or caregiver status.

This e-mail was sent to you because you have provided your e-mail address to CURE. CURE is committed to protecting your privacy and no information about our subscribers is sold to any outside party.

Please add curextra@curetoday.com to your address book or safe sender list to ensure this e-mail is delivered to your inbox.

© 2009 CURE Media Group. All rights reserved. Terms of Use

Disclaimer: CURE does not provide medical, diagnostic, or treatment advice.


Herceptin advertisement


Take our survey